This Article Full Text Full Text (PDF) All Versions of this Article: 92/6/2374    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Khosravi, A. Articles by Collins, M. T. Search for Related Content PubMed PubMed Citation Articles by Khosravi, A. Articles by Collins, M. T. Related Collections Calcium and Bone Metabolism

Determination of the Elimination Half-Life of Fibroblast Growth Factor-23

Skeletal Clinical Studies Unit (A.K., C.M.C., M.H.K., M.T.C.), Craniofacial and Skeletal Diseases Branch, National Institute of Dental and Craniofacial Research; Department of Radiology (R.C.), Mark O. Hatfield Clinical Center; and Surgery Branch (R.E.R., R.M.S.), National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892; Department of Orthopedics and Pediatrics (F.M.W.), Georgetown University, Washington, D.C.; and Division of Geriatric Medicine and Gerontology (N.S.F.), Department of Medicine, Johns Hopkins University, Baltimore, Maryland 21224

Address all correspondence and requests for reprints to: Michael T. Collins, M.D., Chief, Skeletal Clinical Studies Unit, Craniofacial and Skeletal Diseases Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Building 30, Room 228 MSC 4320, Bethesda, Maryland 20892-4320. E-mail: mc247k{at}nih.gov.

Context: Tumor-induced osteomalacia (TIO) is a rare paraneoplastic disease caused by mesenchymal tumors that secrete fibroblast growth factor-23 (FGF-23), a newly-described vitamin D and phosphate-regulating hormone. Surgical removal of the tumor, the ectopic source of circulating FGF-23, offers the opportunity to determine the elimination half-life of FGF-23.

Objective: The aim of the study was to determine the elimination half-life of FGF-23.

Patients/Methods: The tumors were removed from three patients with TIO, and serum samples were taken every 30 min for up to 72 h after the operation. FGF-23 was measured by both a C-terminal/intact assay and an intact assay, and the elimination half-life was determined by one phase exponential decay methodology.

Setting: The Mark O. Hatfield Clinical Research Center of the National Institutes of Health, a tertiary referral clinical research center, was the setting for the study.

Results: The elimination life of FGF-23 as determined by C-terminal/intact and intact assays was 46 ± 12 and 58 ± 34 min, respectively.

Conclusions: The plasma half-life of serum FGF-23 is in the range of 46–58 min.

This article has been cited by other articles:

				G. van Boekel, J. Ruinemans-Koerts, F. Joosten, P. Dijkhuizen, A. van Sorge, and H. de Boer Tumor producing fibroblast growth factor 23 localized by two-staged venous sampling Eur. J. Endocrinol., March 1, 2008; 158(3): 431 - 437. [Abstract] [Full Text] [PDF]